Kyverna Therapeutics filings document a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its Form 8-K disclosures frequently cover Regulation FD updates for miv-cel clinical data, business and financial results, and material corporate events involving leadership, board composition, and commercial organization changes.
The company's proxy and governance filings describe director elections, board committees, executive compensation, stockholder voting matters, and equity incentive arrangements, including inducement awards. SEC records also identify Kyverna's Nasdaq-listed common stock and provide formal disclosure around its CAR T development strategy, clinical programs in neuroimmunology, capital planning, risk factors, and public-company governance.
Kyverna Therapeutics (KYTX) entered a non-dilutive term loan facility of up to $150.0 million with Oxford Finance, structured in multiple tranches. The facility includes an initial $40.0 million tranche and two additional tranches totaling $60.0 million, with a discretionary fourth tranche of $50.0 million. The company expects to draw $25.0 million from the first tranche on November 3, 2025.
The loan matures on October 1, 2030 and bears a floating rate equal to the greater of the 1‑Month CME Term SOFR or 3.75%, plus 5.00%. Kyverna will make interest-only payments until November 1, 2028 or, at its option upon meeting certain milestones, until November 1, 2029, after which principal and interest are due monthly. The agreement is secured by substantially all assets, including intellectual property, and includes customary events of default.
The company also announced it now expects to report topline registrational data for its Phase 2 KYV‑101 trial in stiff person syndrome in early 2026.
Kyverna Therapeutics (KYTX) announced positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis. The company will host a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the results.
Slides for the call are furnished as Exhibit 99.1. The information was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act.
Kyverna Therapeutics (KYTX) announced positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial evaluating KYV-101 in generalized myasthenia gravis. The company scheduled a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the results. The announcement was provided under Regulation FD to ensure broad, simultaneous disclosure.
The details were furnished as Exhibit 99.1 and, consistent with Regulation FD practice, are not deemed “filed” for purposes of Section 18 of the Exchange Act. This signals a clinical program update rather than a change to financial statements or guidance. The filing lists the press release and the Inline XBRL cover page as exhibits.
Kyverna Therapeutics, Inc. reported a change in its board leadership. Steve Liapis, Ph.D. notified the company on September 19, 2025 that he will resign as a member of the board of directors and all related committees, effective September 30, 2025. The company states that his resignation is not due to any disagreement with its operations, policies, or practices.
After his departure, the size of the board will be reduced from eight to seven directors. The board has appointed current director Christi Shaw to the Audit Committee to fill the vacancy created by Dr. Liapis’ resignation. The board also expressed appreciation for Dr. Liapis’ years of service and contributions.
Kyverna Therapeutics is a clinical-stage biopharma developing CAR T cell therapies for autoimmune diseases. For the quarter ended June 30, 2025, the company reported a net loss of $42.1 million and a six-month net loss of $86.7 million, with net loss per share of $0.97 for the quarter. Accumulated deficit stood at $350.2 million. As of June 30, 2025, Kyverna held $53.4 million in cash and $158.2 million in available-for-sale marketable securities, totaling $211.7 million of liquidity; management estimates this funding is sufficient for at least the next 12 months and into 2027 under the current plan.
Operationally, Kyverna completed enrollment in its registrational Phase 2 KYSA-8 study for stiff person syndrome in Q2 2025 and expects data in the first half of 2026. The KYSA-6 trial in myasthenia gravis has completed enrollment, interim data are planned for Q4 2025, and the trial is being expanded to include a Phase 3 portion expected to begin enrollment by year-end 2025. The company also noted FDA alignment on CMC readiness and plans to support a BLA filing for SPS in the first half of 2026. The company faces securities class and derivative litigation; no loss accruals were recorded as of June 30, 2025.
Kyverna Therapeutics, Inc. furnished a press release providing a business update and reporting financial results for the quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1.
The company notes this information is furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into registration statements. Kyverna's common stock trades on Nasdaq under the symbol KYTX, and the registrant is identified as an emerging growth company.
Kyverna Therapeutics (ticker KYTX) filed a Form 4 disclosing that its Chief Financial Officer, Marc Grasso, received an equity award on 30 June 2025. The transaction involves a single grant of 450,000 stock options with an exercise price of $3.07 and an expiration date of 30 June 2035.
The vesting schedule follows a standard four-year pattern: 25 % (112,500 options) vests on 30 June 2026, after which 1⁄48 of the total options (9,375 shares) vest monthly for the next 36 months, contingent on Grasso’s continued employment. The filing shows direct ownership (D) of the derivative security, and no other changes to common-stock holdings were reported.
This award aligns the CFO’s incentives with long-term shareholder value creation and signals a retention commitment by the company. If fully exercised, the award would add up to 450,000 new common shares to the float, a modest potential dilution given Kyverna’s recent post-IPO share count of roughly 55-60 million (based on prior filings). No cash transactions were reported, and the filing contains no earnings or operational updates.